Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

Major Program(s) or Research Group(s)

  • Community Oncology and Prevention Trials
  • NCI Community Oncology Research Program
  • Supportive Care and Symptom Management

Sponsor

Alliance for Clinical Trials in Oncology

Status

Active, not recruiting

ClinicalTrials.gov ID

For more information, see ClinicalTrials.gov NCT03087708

This randomized pilot clinical trial studies the side effects and best dose of naloxegol and to see how well it works in treating patients with stage IIIB-IV non-small cell lung cancer. Naloxegol may relieve some of the side effects of opioid pain medication and fight off future growth in the cancer.

Intervention

Laboratory Biomarker Analysis, Naloxegol, Placebo, Quality-of-Life Assessment

Condition

Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer

Investigators

Pankaj Gupta, MD

See list of participating sites